Endothelins release tissue plasminogen activator and prostanoids

Area of Science:

• Cardiovascular Physiology
• Endocrinology
• Hemostasis and Thrombosis

Background:

• Endothelin (ET) peptides are potent vasoactive substances.
• Their specific roles in platelet aggregation, fibrinolysis, and hemodynamics require further elucidation.

Purpose of the Study:

• To investigate the effects of Endothelin-1, -2, and -3 on platelet aggregation, fibrinolysis, and hemodynamic parameters in an ex vivo rabbit model.
• To explore the mechanisms underlying these effects, particularly the involvement of prostanoids and tissue plasminogen activator.

Main Methods:

• Administration of varying doses of ET-1, ET-2, and ET-3 to anesthetized rabbits.
• Ex vivo assessment of platelet aggregation induced by adenosine diphosphate (ADP), collagen, and arachidonic acid.
• Measurement of euglobulin clot lysis time to assess fibrinolytic activity.
• Monitoring of left ventricular systolic pressure (LVSP) to evaluate hemodynamic responses.
• Administration of indomethacin to investigate the role of prostanoids.

Main Results:

• ET-1, ET-2, and ET-3 dose-dependently inhibited ADP-induced platelet aggregation ex vivo, an effect abolished by indomethacin.
• No significant effect on in vitro platelet aggregation was observed.
• All three ET peptides significantly reduced euglobulin clot lysis time, indicating enhanced plasma fibrinolytic activity.
• Hemodynamic responses, including transient decreases and prolonged changes in LVSP, were modulated by prostanoid release, as shown by indomethacin's effects.

Conclusions:

• Endothelin peptides exhibit anti-aggregatory effects on platelets and enhance plasma fibrinolytic activity in vivo, likely mediated by prostacyclin and tissue plasminogen activator release.
• The observed hemodynamic effects of Endothelin peptides are influenced by the release of prostanoids.
• These findings highlight the complex roles of Endothelin peptides in regulating hemostasis and cardiovascular function.